Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenues (Tables)

Revenues (Tables)

3 Months Ended

Mar. 31, 2020

Schedule of revenues disaggregated by category

Revenues disaggregated by category were as follows (in thousands):


	Three Months Ended
	March 31,
	2020		2019
Product sales:
Gross product sales	$	15,371	$	9,916
Discounts and allowances		(2,691)		(1,862)
Product sales, net	$	12,680	$	8,054

Revenues from collaborations:
License revenues		39,858		4,499
Research and development services and others		3,223		71
Total revenues from collaborations		43,081		4,570
Total revenues	$	55,761	$	12,624

Schedule of revenues from product sales disaggregated by customers

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a percentage of total revenues):


	Three Months Ended
	March 31,
	2020		2019
Grifols		77%		36%
ASD Healthcare and Oncology Supply		12%		33%
McKesson Specialty Care Distribution Corporation		9%		24%

Schedule of product revenue allowance and reserve categories

The following table summarizes activity in each of the product revenue allowance and reserve categories for the three months ended March 31, 2020 and 2019 (in thousands):


	Chargebacks,		Government
	Discounts and		and Other
	Fees		Rebates		Returns		Total
Balance at January 1, 2020	$	1,293	$	1,801	$	238	$	3,332
Provision related to current period sales		1,487		745		—		2,232
Credit or payments made during the period		(1,324)		(627)		(58)		(2,009)
Balance at March 31, 2020	$	1,456	$	1,919	$	180	$	3,555


	Chargebacks,		Government
	Discounts and		and Other
	Fees		Rebates		Returns		Total
Balance at January 1, 2019	$	622	$	843	$	170	$	1,635
Provision related to current period sales		855		706		99		1,660
Credit or payments made during the period		(735)		(323)		—		(1,058)
Balance at March 31, 2019	$	742	$	1,226	$	269	$	2,237